No Data
KPC Group: KPC Annual Report 2024 (Revised Edition)
KPC Pharmaceuticals, Inc. 2024 Annual Report (Revised Edition)
Nomura Orient Starts KPC Pharmaceuticals at Overweight With 23.75 Yuan Price Target
We Think KPC PharmaceuticalsInc (SHSE:600422) Can Manage Its Debt With Ease
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
KPC PharmaceuticalsInc's (SHSE:600422) Investors Will Be Pleased With Their Respectable 86% Return Over the Last Five Years
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing